Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Buprenorphine Transdermal System in Chronic Pain
NCT01151098Phase 3Completed
- Sponsor
- Purdue Pharma
- Start
- Apr 2001
- Primary completion
- Feb 2002
- Modality
- Orthosteric Ligands, Inhalation Devices
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of v1003 in chronic pain, sponsored by Purdue Pharma. Primary endpoint: Number of Participants With Adverse Events at 28 weeks. Started Apr 2001; status: completed.
02
Drugs
v1003
03
Conditions
chronic pain
Beyond the preview
Go deeper on NCT01151098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01151098.